PEG10 Promoter-Driven Expression of Reporter Genes Enables Molecular Imaging of Lethal Prostate Cancer.
Apoptosis Regulatory Proteins
/ genetics
Cell Line, Tumor
DNA-Binding Proteins
/ genetics
Gene Expression Regulation, Neoplastic
/ genetics
Genes, Reporter
/ genetics
Humans
Male
Molecular Imaging
/ methods
PC-3 Cells
Promoter Regions, Genetic
/ genetics
Prostate-Specific Antigen
/ genetics
Prostatic Neoplasms
/ genetics
Protein Isoforms
/ genetics
RNA Splicing
/ genetics
RNA-Binding Proteins
/ genetics
Receptors, Androgen
/ genetics
Journal
Cancer research
ISSN: 1538-7445
Titre abrégé: Cancer Res
Pays: United States
ID NLM: 2984705R
Informations de publication
Date de publication:
01 11 2019
01 11 2019
Historique:
received:
21
07
2019
revised:
30
08
2019
accepted:
13
09
2019
pubmed:
19
9
2019
medline:
29
5
2020
entrez:
19
9
2019
Statut:
ppublish
Résumé
The retrotransposon-derived paternally expressed gene 10 (PEG10) protein is ordinarily expressed at high levels in the placenta. Recently, it was discovered that PEG10 isoforms promote the progression of prostate cancer to a highly lethal androgen receptor (AR)-negative phenotype. The presence of PEG10 in other subtypes of prostate cancer has not been explored and a utility for PEG10 overexpression has not been developed. Here, we found that in addition to AR-null disease, PEG10 was also expressed in prostate cancer with constitutively active AR-splice variants. A molecular genetic imaging strategy for noninvasive imaging of AR-splice variant prostate cancer was developed by utilizing the cancer specificity of the PEG10 promoter to drive the expression of reporter genes. Plasmid insertion of a PEG10 promoter sequence optimized for enhanced output upstream of a reporter gene allowed detection of prostate cancer by near-infrared and positron emission tomography imaging after systemic administration of the plasmid
Identifiants
pubmed: 31530569
pii: 0008-5472.CAN-19-2181
doi: 10.1158/0008-5472.CAN-19-2181
pmc: PMC6825593
mid: NIHMS1540444
doi:
Substances chimiques
Apoptosis Regulatory Proteins
0
DNA-Binding Proteins
0
PEG10 protein, human
0
Protein Isoforms
0
RNA-Binding Proteins
0
Receptors, Androgen
0
Prostate-Specific Antigen
EC 3.4.21.77
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
5668-5680Subventions
Organisme : NCI NIH HHS
ID : K12 CA090628
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA174777
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA233562
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA237272
Pays : United States
Informations de copyright
©2019 American Association for Cancer Research.
Références
J Gene Med. 2002 Jan-Feb;4(1):84-91
pubmed: 11828391
Curr Oncol Rep. 2017 May;19(5):32
pubmed: 28361223
Endocr Relat Cancer. 2018 Oct 1;26(2):131-146
pubmed: 30400059
Arch Gynecol Obstet. 2017 Mar;295(3):751-761
pubmed: 28154921
J Genet Syndr Gene Ther. 2013 Aug 9;4:null
pubmed: 24294541
Nat Protoc. 2006;1(6):3069-75
pubmed: 17406570
Nat Med. 2016 Apr;22(4):369-78
pubmed: 26928463
Proc Natl Acad Sci U S A. 2013 Oct 22;110(43):17492-7
pubmed: 24101480
Genome Res. 2011 Jan;21(1):56-67
pubmed: 21036922
EMBO J. 1992 Dec;11(13):5005-12
pubmed: 1464322
Cancer Res. 2014 Oct 15;74(20):5772-81
pubmed: 25145668
Semin Nucl Med. 2016 Nov;46(6):491-501
pubmed: 27825429
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Nat Med. 2018 Dec;24(12):1887-1898
pubmed: 30478421
Nat Med. 2008 Aug;14(8):882-8
pubmed: 18622403
Oncotarget. 2015 Jan 1;6(1):234-42
pubmed: 25428917
Cancer Res. 2009 Mar 15;69(6):2305-13
pubmed: 19244107
Cancers (Basel). 2017 Jun 12;9(6):null
pubmed: 28604629
Oncotarget. 2018 Nov 30;9(94):36693-36704
pubmed: 30613352
Oncotarget. 2017 Mar 14;8(11):18550-18576
pubmed: 28077788
J Urol. 2014 Jun;191(6):1697-702
pubmed: 24342146
Clin Cancer Res. 2014 Jul 15;20(14):3692-704
pubmed: 24850844
Cell Rep. 2015 Aug 11;12(6):922-36
pubmed: 26235627
Nat Genet. 2006 Jan;38(1):101-6
pubmed: 16341224
Nat Protoc. 2008;3(6):1101-8
pubmed: 18546601
Genes Dev. 1988 Jun;2(6):718-29
pubmed: 2843425
Clin Cancer Res. 2014 Jun 1;20(11):2846-50
pubmed: 24727321
Nat Commun. 2019 Jan 17;10(1):278
pubmed: 30655535
Neurol Sci. 2006 Sep;27(4):252-6
pubmed: 16998728
Nat Med. 2011 Jan;17(1):123-9
pubmed: 21151140
Proc Natl Acad Sci U S A. 2018 May 8;115(19):E4473-E4482
pubmed: 29686080
Nat Methods. 2013 Aug;10(8):751-4
pubmed: 23770755
PLoS One. 2010 Jan 13;5(1):e8686
pubmed: 20084274
Adv Cancer Res. 2014;124:131-69
pubmed: 25287688
Gene Ther. 2010 Nov;17(11):1325-32
pubmed: 20428214
Nat Protoc. 2006;1(4):2137-42
pubmed: 17487205
Clin Cancer Res. 2017 Aug 15;23(16):4704-4715
pubmed: 28473535
Clin Cancer Res. 2018 Aug 1;24(15):3668-3680
pubmed: 29716922
Endocrinology. 2013 Nov;154(11):4010-7
pubmed: 24002034
Cancer Gene Ther. 2012 Jun;19(6):374-81
pubmed: 22498722
Clin Genitourin Cancer. 2017 Feb;15(1):e65-e68
pubmed: 27751686
JAMA. 2005 Jul 13;294(2):238-44
pubmed: 16014598
Clin Cancer Res. 2017 Mar 15;23(6):1542-1551
pubmed: 27663589
Mol Ther. 2002 Mar;5(3):223-32
pubmed: 11863411
J Virol Methods. 2003 May;109(2):177-86
pubmed: 12711061
Development. 2001 Jul;128(13):2593-602
pubmed: 11493575
AJR Am J Roentgenol. 2009 Jun;192(6):1455-70
pubmed: 19457806
Mol Ther. 2015 Apr;23(4):779-89
pubmed: 25586689
Oncol Rep. 2011 Oct;26(4):769-75
pubmed: 21725614
Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14595-600
pubmed: 11734653
Curr Opin Oncol. 2012 May;24(3):251-7
pubmed: 22327838
Cancer Res. 2013 Jan 15;73(2):483-9
pubmed: 23117885
JAMA Oncol. 2017 Oct 1;3(10):1415-1422
pubmed: 28097325
Cell. 2015 Jul 16;162(2):454
pubmed: 28843286
Proc Natl Acad Sci U S A. 2005 Jan 25;102(4):1145-50
pubmed: 15653773
Cancer Res. 2011 Oct 1;71(19):6250-60
pubmed: 21933883
Prostate. 2017 May;77(6):654-671
pubmed: 28156002
Prostate. 2002 Jun 1;52(1):20-33
pubmed: 11992617